Genscript Bio (01548): The amendment of the deposit agreement led to the termination of the merger with Legend Biotech Co., Ltd. and its subsidiaries.
Genscript Bio (01548) announced that on October 18, 2024 (New York time), Legend...
Genscript Biotech Announces Deconsolidation of Legend Biotech
Legend Biotech | 6-K: Report of foreign private issuer (related to financial reporting)
Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
Strategic Growth and Promising Prospects Drive Buy Rating for Legend Biotech
US stock market outlook: Chinese assets collectively rise before the market! YINN surged more than 15%, bilibili rose more than 7%; Goldman Sachs: debt conversion is the first step in China's fiscal big move, which will stimulate economic growth.
Trump claimed to have received a 'plea for help' call from Cook, involving Apple being fined heavily by the European Union; Is there still an 'undercurrent' behind the bull market of US stocks? Goldman Sachs: The rise of the US dollar is a major threat; The gold price continues to hit new highs! As risk aversion heats up, spot gold rises above $2,700.
Central Bank's major announcement! Reserve ratio cut, interest rate cut, officially launching share buyback and shareholding refinancing.
Pan Gongsheng stated that it is expected to carefully assess the market liquidity situation before the end of the year, and opportunistically further lower the deposit reserve ratio by 0.25-0.5 percentage points; reduce the open market 7-day reverse repurchase operation rate by 0.2 percentage points.
Scotiabank Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $76
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $73 to $94
9 Analysts Have This To Say About Legend Biotech
Legend Biotech (LEGN) Gets a Buy From Scotiabank
Legend Biotech Price Target Maintained With a $73.00/Share by HC Wainwright & Co.
Positive Outlook and Buy Rating for Legend Biotech Driven by CARVYKTI's Strong Performance and Market Edge
Genscript Bio announced that CARVYKTI's third-quarter net trade sales amounted to approximately 0.286 billion US dollars.
Genscript Bio (01548) announced that Legend Biotech Co., Ltd. (Legend Biotech, a non-wholly owned subsidiary of the company, whose shares are listed on the Nasdaq Global Select Market in the United States in the form of American depositary shares) submitted a 6-K form to the U.S. Securities and Exchange Commission (SEC) on October 15, 2024 (New York time, after the Hong Kong trading hours on October 15, 2024).
Johnson & Johnson Posts Q3 Beat; Lowers Earnings Guidance Amid M&A Impact
Express News | Legend Biotech Corp - Carvykti Generated About $286 Mln in Net Trade Sales During Qtr Ended Sept 30
Jefferies Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $94
TD Cowen Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $67
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Redburn Initiates Legend Biotech at Buy With $86 Price Target